ciprofloxacin has been researched along with Cholangitis in 19 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Cholangitis: Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the role of ciprofloxacin in reducing cholangitis in cholestatic patients with adequate biliary drainage after endoscopic retrograde cholangiopancreatography (ERCP)." | 9.12 | Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography. ( Chantawibul, S; Leelawat, K; Panpimanmas, S; Prajanphanit, P; Ratanachu-ek, T; Subwongcharoen, S; Wannaprasert, J, 2007) |
| "One hundred consecutive patients with acute suppurative cholangitis were randomized in a prospective, controlled clinical trial to receive either ciprofloxacin (200 mg bd iv) or triple therapy comprising ceftazidime (1 g bd iv), ampicillin (500 mg qds iv) and metronidazole (500 mg tds iv); 46 and 44 patients in the ciprofloxacin and triple therapy groups respectively were suitable for inclusion in the analysis of efficacy." | 9.08 | Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. ( Cheng, AF; Chung, SC; Co, AL; Leung, JW; Li, AK; Lyon, DJ; Suen, R; Sung, JJ, 1995) |
| "To compare the efficacy and safety of oral ciprofloxacin and intravenous cefuroxime in patients at high risk of cholangitis after endoscopic retrograde cholangiopancreatography (ERCP)." | 9.08 | Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis. ( Chapman, RW; Culshaw, KD; Mehal, WZ; Tillotson, GS, 1995) |
| "To evaluate drug and indication specific off-label use in paediatrics, applied to ciprofloxacin (CPFX) in cholangitis." | 7.77 | Off-label drug use evaluation in paediatrics--applied to ciprofloxacin when used as treatment of cholangitis. ( Lindemalm, S; Nemeth, A; Nydert, P, 2011) |
| "This study investigates the potential benefits of antibiotics and N-acetylcysteine (NAC), a mucolytic agent, in patients who are candidates for endoscopic retrograde cholangiopancreatography (ERCP) due to partial bile duct obstruction." | 5.14 | Potential benefits of combined N-acetylcysteine and ciprofloxacin therapy in partial biliary obstruction. ( Akkiz, H; Cosar, A; Kece, C; Ozdil, B; Sandikci, M, 2010) |
| "To determine the role of ciprofloxacin in reducing cholangitis in cholestatic patients with adequate biliary drainage after endoscopic retrograde cholangiopancreatography (ERCP)." | 5.12 | Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography. ( Chantawibul, S; Leelawat, K; Panpimanmas, S; Prajanphanit, P; Ratanachu-ek, T; Subwongcharoen, S; Wannaprasert, J, 2007) |
| " In each follow-up visit, clinical symptoms of cholangitis were documented and blood samples taken for blood counts, serum levels of bilirubin, and alkaline phosphatase." | 5.09 | Long-term ciprofloxacin treatment for the prevention of biliary stent blockage: a prospective randomized study. ( Chung, SC; Ismael, A; Lai, CW; Sollano, JD; Sung, JJ; Tumala, I; Yung, MY, 1999) |
| "One hundred consecutive patients with acute suppurative cholangitis were randomized in a prospective, controlled clinical trial to receive either ciprofloxacin (200 mg bd iv) or triple therapy comprising ceftazidime (1 g bd iv), ampicillin (500 mg qds iv) and metronidazole (500 mg tds iv); 46 and 44 patients in the ciprofloxacin and triple therapy groups respectively were suitable for inclusion in the analysis of efficacy." | 5.08 | Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. ( Cheng, AF; Chung, SC; Co, AL; Leung, JW; Li, AK; Lyon, DJ; Suen, R; Sung, JJ, 1995) |
| "To compare the efficacy and safety of oral ciprofloxacin and intravenous cefuroxime in patients at high risk of cholangitis after endoscopic retrograde cholangiopancreatography (ERCP)." | 5.08 | Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis. ( Chapman, RW; Culshaw, KD; Mehal, WZ; Tillotson, GS, 1995) |
| "Oral ciprofloxacin is a cost-effective prophylactic agent for high-risk ERCP." | 2.69 | Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients. ( Alveyn, CG; Davis, AJ; Kolios, G; Robertson, DA, 1998) |
| "The cornerstone of treatment for acute cholangitis is source control with biliary drainage and early antibiotics." | 1.72 | Microbiology of bile aspirates obtained at ERCP in patients with suspected acute cholangitis. ( Beeler, C; Bick, BL; Easler, JJ; Fogel, EL; Gromski, MA; Gutta, A; Lehman, GA; McHenry, L; Relich, RF; Schmitt, BH; Sherman, S; Tong, Y; Watkins, JL, 2022) |
| "Cholangitis is a frequent complication of biliary stents." | 1.31 | Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. ( Esber, E; Fogel, EL; Kalayci, C; Lehman, GA; Rerknimitr, R; Sherman, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Gromski, MA | 1 |
| Gutta, A | 1 |
| Lehman, GA | 2 |
| Tong, Y | 1 |
| Fogel, EL | 2 |
| Watkins, JL | 1 |
| Easler, JJ | 1 |
| Bick, BL | 1 |
| McHenry, L | 1 |
| Beeler, C | 1 |
| Relich, RF | 1 |
| Schmitt, BH | 1 |
| Sherman, S | 2 |
| Ozdil, B | 1 |
| Kece, C | 1 |
| Cosar, A | 1 |
| Akkiz, H | 1 |
| Sandikci, M | 1 |
| Varadarajulu, S | 1 |
| Nydert, P | 1 |
| Lindemalm, S | 1 |
| Nemeth, A | 1 |
| Rerknimitr, R | 1 |
| Kalayci, C | 1 |
| Esber, E | 1 |
| Linde, H | 1 |
| Lehn, N | 1 |
| Chan, G | 1 |
| Barkun, J | 1 |
| Barkun, AN | 1 |
| Valois, E | 1 |
| Cohen, A | 1 |
| Friedman, G | 1 |
| Parent, J | 1 |
| Love, J | 1 |
| Enns, R | 1 |
| Baffis, V | 1 |
| Jabbari, M | 1 |
| Szego, P | 1 |
| Stein, L | 1 |
| Abraham, N | 1 |
| Bukharin, OV | 1 |
| Gritsenko, VA | 1 |
| Tret'iakov, AA | 1 |
| Chernikov, DA | 1 |
| Ratanachu-ek, T | 1 |
| Prajanphanit, P | 1 |
| Leelawat, K | 1 |
| Chantawibul, S | 1 |
| Panpimanmas, S | 1 |
| Subwongcharoen, S | 1 |
| Wannaprasert, J | 1 |
| Vogel, Y | 1 |
| Tannapfel, A | 1 |
| Rabsch, W | 1 |
| Henning, B | 1 |
| Dhalluin-Venier, V | 1 |
| Bazin, C | 1 |
| Massias, L | 1 |
| Farah, RB | 1 |
| Boytchev, I | 1 |
| Fritsch, J | 1 |
| Choury, AD | 1 |
| Prat, F | 1 |
| Buffet, C | 1 |
| Furlan, V | 1 |
| Pelletier, G | 1 |
| Sung, JJ | 2 |
| Lyon, DJ | 1 |
| Suen, R | 1 |
| Chung, SC | 2 |
| Co, AL | 1 |
| Cheng, AF | 1 |
| Leung, JW | 1 |
| Li, AK | 1 |
| Mehal, WZ | 1 |
| Culshaw, KD | 1 |
| Tillotson, GS | 1 |
| Chapman, RW | 1 |
| Marmorale, A | 1 |
| Mainguene, C | 1 |
| Gavelli, A | 1 |
| Huguet, C | 1 |
| Demediuk, B | 1 |
| Speer, AG | 1 |
| Hellyar, A | 1 |
| Davis, AJ | 1 |
| Kolios, G | 1 |
| Alveyn, CG | 1 |
| Robertson, DA | 1 |
| Sollano, JD | 1 |
| Lai, CW | 1 |
| Ismael, A | 1 |
| Yung, MY | 1 |
| Tumala, I | 1 |
| Houwen, RH | 1 |
| Bijleveld, CM | 1 |
| de Vries-Hospers, HG | 1 |
| Lonka, L | 1 |
| Pedersen, RS | 1 |
8 trials available for ciprofloxacin and Cholangitis
| Article | Year |
|---|---|
Potential benefits of combined N-acetylcysteine and ciprofloxacin therapy in partial biliary obstruction.
Topics: Acetylcysteine; Aged; Anti-Infective Agents; Bile Ducts; Bilirubin; C-Reactive Protein; Cholangiopan | 2010 |
The role of ciprofloxacin in prolonging polyethylene biliary stent patency: a multicenter, double-blinded effectiveness study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Biliary Tract Neoplas | 2005 |
Role of ciprofloxacin in patients with cholestasis after endoscopic retrograde cholangiopancreatography.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Bile; Cholangiopancreatography, Endoscopic Retrograde; | 2007 |
Effects of biliary obstruction on the penetration of ciprofloxacin and cefotaxime.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bile; Bilirubin; Cefotaxime; Cholangiopancreatograph | 2008 |
Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial.
Topics: Acute Disease; Aged; Bacteria; Bile; Biliary Tract; Cholangitis; Ciprofloxacin; Double-Blind Method; | 1995 |
Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis.
Topics: Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Cefuroxime; Cephalosporins; Cholangiopan | 1995 |
Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bile; C | 1998 |
Long-term ciprofloxacin treatment for the prevention of biliary stent blockage: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Anti-Infective Agents; Bile Duct Neoplasms; Bi | 1999 |
11 other studies available for ciprofloxacin and Cholangitis
| Article | Year |
|---|---|
Microbiology of bile aspirates obtained at ERCP in patients with suspected acute cholangitis.
Topics: Anti-Bacterial Agents; Bile; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis; Ciproflox | 2022 |
Antibiotic prophylaxis is recommended for endoscopic ultrasound-guided fiducial placements.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Cholangitis; Ciprofloxacin; Endosonography; Hum | 2011 |
Off-label drug use evaluation in paediatrics--applied to ciprofloxacin when used as treatment of cholangitis.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Cholangitis; Ciprofloxacin; Data Collect | 2011 |
Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bile; Chil | 2002 |
[Methicillin-resistant Staphylococcus aureus (MRSA) -- case report].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Cholangitis; Ciprofloxacin; Humans; Male; Methic | 2005 |
[Taxonomic spectrum and antibiotic resistance of Enterobacteriaceae isolated from bile of patients with cholangitis].
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Amoxicillin; Anti-Bacterial Agents; Bile; Cefazolin; Cefot | 2006 |
[Cholangitis with hepatic microabscesses caused by Salmonella enterica serovar choleraesuis].
Topics: Aged; Anti-Bacterial Agents; C-Reactive Protein; Cholangitis; Ciprofloxacin; Diagnosis, Differential | 2007 |
[Pure angiocholitic form of congenital hepatic fibrosis].
Topics: Anti-Infective Agents; Cholangitis; Ciprofloxacin; Combined Modality Therapy; Female; Humans; Liver | 1996 |
Induced antibiotic-resistant bacteria in cholangitis with biliary stasis.
Topics: Aged; Anti-Infective Agents; Cholangitis; Cholestasis; Ciprofloxacin; Enterobacter cloacae; Enteroba | 1996 |
Ciprofloxacin for cholangitis after hepatic portoenterostomy.
Topics: Biliary Atresia; Cholangitis; Ciprofloxacin; Escherichia coli Infections; Female; Humans; Infant; Kl | 1987 |
Ciprofloxacin for cholangitis.
Topics: Aged; Cholangitis; Ciprofloxacin; Escherichia coli Infections; Female; Humans; Recurrence | 1987 |